Ira Mellman, PhD, President of Research, to receive SITC's Richard V. Smalley Memorial Award for his significant ...

Researchers can use messenger RNA to trigger the immune system to attack tumors. By stimulating cancer cells to produce a ...

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate ...

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate ...

How AI, robotics, and precision medicine are transforming cancer care—bridging hope, technology, and humanity in the ongoing ...

NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...

T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of all adult cancers, remain a ...

Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...

Gene editing techniques, including CRISPR, prime editing, and nucleases, allow scientists to tackle genetic diseases, cancer, ...